Back to results
US 2026/0137774 A1Published application
Hepatitis B Virus Receptor OATP and Use Thereof
AssigneeShanghai Hep Pharmaceutical Co., Ltd.
InventorHongli LIU
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeShanghai Hep Pharmaceutical Co., Ltd.
InventorHongli LIU
Estimating the term…
Provided in the present invention are a hepatitis B virus receptor OATP and the use thereof. Specifically, provided in the present invention is the use of a substance in the preparation of an agent for preventing and/or treating hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in an animal or diseases related to said infections, wherein the substance prevents or reduces the interaction between HBV and/or HDV and an organic anion transporting polypeptide (OATP) in the animal, and/or prevents or reduces the expression and/or function of OATP in the animal. Further provided in the present invention are a cell model and an animal model having susceptibility to HBV and/or HDV that are obtained by means of transferring an exogenous SLCO gene into a cell or expressing an exogenous OATP protein, and a method for establishing the models; a method for delivering a drug by means of targeting OATP, and a drug delivery vehicle targeting OATP; and an OATP-targeted delivery polypeptide vehicle derived from a hepadnaviridae surface antigen.
A method for preventing and/or treating hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections or diseases related to said infections in an animal, comprising administering to the animal a substance that prevents or reduces the interaction between HBV and/or HDV and an organic anion transporting polypeptide (OATP) in the animal, and/or prevents or reduces the expression and/or function of OATP in the animal.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-24. (canceled)
A drug or group delivery vehicle, wherein, the vehicle at least retains the biological activity of binding OATP and delivering the carried drug or group into cells.
-34. (canceled)
-39. (canceled)
-45. (canceled)
-59. (canceled)
A method for optimizing a pharmacokinetic of a therapeutic agent, such as statins, sartans, tinibs, and anti-cancer drugs tumor drugs such as platinum or paclitaxel drugs in an animal, comprising administering to the animal a polypeptide and the statins, sartans, tinibs, and anti-cancer drugs, wherein:
Dependencies are inferred from the claim text.